Viatris Inc. logo

Viatris Inc. (0A5V)

Market Closed
15 Oct, 03:30 PM
$
18. 15
+0.55
+3.125%
$
- Market Cap
6.8 P/E Ratio
0.41% Div Yield
11,694 Volume
2.95 Eps
$ 17.6
Previous Close
Add Transaction
Day Range
17.38 18.18
Year Range
9.87 18.64
Want to track 0A5V and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

0A5V closed yesterday higher at $18.15, an increase of 3.125% from Wednesday's close, completing a monthly increase of 2.5424% or $0.45. Over the past 12 months, 0A5V stock gained 44.9102%.
0A5V pays dividends to its shareholders, with the most recent payment made on Sep 16, 2026. The next estimated payment will be in In 2 months on Dec 16, 2026 for a total of $0.12.
The last earnings report, released on May 07, 2026, missed the consensus estimates by -0.51%. On average, the company has fell short of earnings expectations by -0.52%, based on the last three reports.
Viatris Inc. has completed 10 stock splits, with the recent split occurring on Oct 09, 2003.
The company's stock is traded on 11 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

0A5V Chart

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.

Zacks | 1 week ago
Viatris to Buy Pacira BioSciences for $1.65 Billion

Viatris to Buy Pacira BioSciences for $1.65 Billion

Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in a deal that expands the healthcare company's medicines portfolio.

Wsj | 1 week ago
VTRS vs. AVTR: Which Stock Is the Better Value Option?

VTRS vs. AVTR: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical Services sector might want to consider either Viatris (VTRS) or Avantor, Inc. (AVTR). But which of these two stocks is more attractive to value investors?

Zacks | 1 week ago

Viatris Inc. (0A5V) FAQ

What is the stock price today?

The current price is $18.15.

On which exchange is it traded?

Viatris Inc. is listed on LSE.

What is its stock symbol?

The ticker symbol is 0A5V.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.41%.

What is its market cap?

As of today, no market cap data is available.

Has Viatris Inc. ever had a stock split?

Viatris Inc. had 10 splits and the recent split was on Oct 09, 2003.

Viatris Inc. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Scott Andrew Smith CEO
LSE Exchange
92556V106 CUSIP
US Country
30,000 Employees
21 Aug 2026 Last Dividend
9 Oct 2003 Last Split
16 Nov 2020 IPO Date

Overview

Viatris Inc. is a global healthcare company that has marked its presence worldwide since its foundation in 1961, with its headquarters situated in Canonsburg, Pennsylvania. The company operates across various segments globally, including Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. Viatris is committed to providing access to medicines, sustainable operations, and community support, focusing on addressing the needs of patients in both noncommunicable and infectious disease domains. Its wide array of products stretches from prescription brand drugs to complex generics, biosimilars, and active pharmaceutical ingredients (APIs), catering to a broad spectrum of therapeutic areas and underpinning its mission to empower people worldwide to live healthier at every stage of life.

Products and Services

Viatris Inc.'s expansive portfolio encompasses a diverse range of healthcare solutions, from critical medicines to comprehensive support services, aimed at enhancing patient care and access:

  • Prescription Brand Drugs & Generics: Includes essential medications for various health conditions, ensuring patients have access to quality treatment options.
  • Complex Generic Drugs: Offers complex generics that are equivalent to brand-name drugs, providing more accessible and cost-effective treatment alternatives.
  • Biosimilars: The company produces biosimilars for oncology, immunology, endocrinology, ophthalmology, and dermatology, offering high-quality alternatives to existing biologic drugs.
  • Active Pharmaceutical Ingredients (APIs): APIs for a vast range of therapeutic areas including antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors, highlighting the breadth of Viatris’s capabilities in drug manufacturing.
  • Support Services: Beyond just providing medications, Viatris also facilitates diagnostic clinics, educational seminars, and digital tools to help individuals better manage their health, emphasizing the holistic approach to healthcare.

Medications are delivered in various forms, including oral solid doses, injectables, and complex dosage forms, ensuring versatility in administration ways to suit different patient needs. Distribution channels encompass pharmaceutical wholesalers/distributors, retailers, institutional pharmacies, mail-order, e-commerce, and specialty pharmacies, ensuring broad accessibility. Products like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and the EpiPen auto-injector, among others, highlight the wide range and significance of Viatris’s offering in addressing global health issues. Through partnerships, like with Revance Therapeutics, Inc. and Momenta Pharmaceuticals, Inc., Viatris Inc. continues to expand its portfolio, promising innovation and expanded access to essential medicines for patients worldwide.

Contact Information

Address: Robert J. Coury Global Center
Phone: 724 514 1800